Patents by Inventor Daniel Edward Tracey

Daniel Edward Tracey has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20150071875
    Abstract: Human antibodies, preferably recombinant human antibodies, that specifically bind to human interleukin-12 (hIL-12) are disclosed. Preferred antibodies have high affinity for hIL-12 and neutralize hIL-12 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and for inhibiting hIL-12 activity, e.g., in a human subject suffering from a disorder in which hIL-12 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.
    Type: Application
    Filed: May 21, 2014
    Publication date: March 12, 2015
    Inventors: Jochen G. Salfeld, Michael Roguska, Michael Paskind, Subhashis Banerjee, Daniel Edward Tracey, Michael White, Zehra Kaymakcalan, Boris Labkovsky, Paul Sakorafas, Geertruida M. Veldman, Amy Venturini, Angela Widom, Stuart Friedrich, Nicholas W. Warner, Angela Myles, John Gawain Elvin, Alexander Robert Duncan, Elaine Joy Derbyshire, Sara Carmen, Stephen Smith, Thor Las Holtet, Sarah Du Fou
  • Publication number: 20150037348
    Abstract: Human antibodies, preferably recombinant human antibodies, that specifically bind to human interleukin-12 (hIL-12) are disclosed. Preferred antibodies have high affinity for hIL-12 and neutralize hIL-12 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and for inhibiting hIL-12 activity, e.g., in a human subject suffering from a disorder in which hIL-12 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.
    Type: Application
    Filed: July 10, 2014
    Publication date: February 5, 2015
    Inventors: Jochen G. Salfeld, Michael Roguska, Michael Paskind, Subhashis Banerjee, Daniel Edward Tracey, Michael White, Zehra Kaymakcalan, Boris Labkovsky, Paul Sakorafas, Geertruida M. Veldman, Amy Venturini, Angela Widom, Stuart Friedrich, Nicholas W. Warner, Angela Myles, John Gawain Elvin, Alexander Robert Duncan, Elaine Joy Derbyshire, Sara Carmen, Stephen Smith, Thor Las Holtet, Sarah Du Fou
  • Patent number: 8865174
    Abstract: Human antibodies, preferably recombinant human antibodies, that specifically bind to human interleukin-12 (hIL-12) are disclosed. Preferred antibodies have high affinity for hIL-12 and neutralize hIL-12 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and for inhibiting hIL-12 activity, e.g., in a human subject suffering from a disorder in which hIL-12 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.
    Type: Grant
    Filed: March 12, 2012
    Date of Patent: October 21, 2014
    Assignee: AbbVie Inc.
    Inventors: Jochen G. Salfeld, Michael Roguska, Michael Paskind, Subhashis Banerjee, Daniel Edward Tracey, Michael White, Zehra Kaymakcalan, Boris Labkovsky, Paul Sakorafas, Geertruida M. Veldman, Amy Venturini, Angela Widom, Stuart Friedrich, Nicholas W. Warne, Angela Kantor, John Gawain Elvin, Alexander Robert Duncan, Elaine J. Derbyshire, Sara Carmen, Stephen Smith, Thor Las Holtet, Sarah Leila Du Fou
  • Patent number: 8765918
    Abstract: Human antibodies, preferably recombinant human antibodies, that specifically bind to human interleukin-12 (hIL-12) are disclosed. Preferred antibodies have high affinity for hIL-12 and neutralize hIL-12 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and for inhibiting hIL-12 activity, e.g., in a human subject suffering from a disorder in which hIL-12 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.
    Type: Grant
    Filed: March 23, 2012
    Date of Patent: July 1, 2014
    Assignee: Abbott GmbH & Co., KG
    Inventors: Jochen G. Salfeld, Michael Roguska, Michael Paskind, Subhashis Banerjee, Daniel Edward Tracey, Michael White, Zehra Kaymakcalan, Boris Labkovsky, Paul Sakorafas, Geertruida M. Veldman, Amy Venturini, Angela Widom, Stuart Friedrich, Nicholas W. Warne, Angela Myles, John Gawain Elvin, Alexander Robert Duncan, Elaine Joy Derbyshire, Sara Carmen, Stephen Smith, Thor Las Holtet, Sarah Leila Du Fou
  • Publication number: 20130243786
    Abstract: Methods of treating TNF?-related disorders comprising administering TNF? inhibitors, including TNF? antibodies are described.
    Type: Application
    Filed: July 18, 2003
    Publication date: September 19, 2013
    Applicant: Abbott Biotechnology Ltd.
    Inventors: Subhashis Banerjee, Lori K. Taylor, Clive E. Spiegler, Daniel Edward Tracey, Elliot K. Chartash, Rebecca S. Hoffman, William T. Barchuk, Philip Yan, Anwar Murtaza, Jochen G. Salfeld, Steven Fischkoff
  • Publication number: 20130243763
    Abstract: Methods of treating TNF?-related disorders comprising administering TNF? inhibitors, including TNF? antibodies are described.
    Type: Application
    Filed: May 28, 2013
    Publication date: September 19, 2013
    Inventors: Subhashis Banerjee, Lori K. Taylor, Clive E. Spiegler, Daniel Edward Tracey, Elliot Keith Chartash, Rebecca S. Hoffman, William T. Barchuk, Philip Yan, Anwar Murtaza, Jochen G. Salfeld, Steven A. Fischkoff
  • Publication number: 20120201831
    Abstract: Human antibodies, preferably recombinant human antibodies, that specifically bind to human interleukin-12 (hIL-12) are disclosed. Preferred antibodies have high affinity for hIL-12 and neutralize hIL-12 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and for inhibiting hIL-12 activity, e.g., in a human subject suffering from a disorder in which hIL-12 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.
    Type: Application
    Filed: March 9, 2012
    Publication date: August 9, 2012
    Inventors: Jochen G. Salfeld, Michael Roguska, Michael Paskind, Subhashis Banerjee, Daniel Edward Tracey, Michael White, Zehra Kaymakcalan, Boris Labkovsky, Paul Sakorafas, Geertruida M. Veldman, Amy Venturini, Angela Widom, Stuart Friedrich, Nicholas W. Warne, Angela Kantor, John Gawain Elvin, Alexander Robert Duncan, Elaine Joy Derbyshire, Sara Carmen, Stephen Smith, Thor Las Holtet, Sarah Leila Du Fou
  • Publication number: 20110123544
    Abstract: Human antibodies, preferably recombinant human antibodies, that specifically bind to human interleukin-12 (hIL-12) are disclosed. Preferred antibodies have high affinity for hIL-12 and neutralize hIL-12 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and for inhibiting hIL-12 activity, e.g., in a human subject suffering from a disorder in which hIL-12 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.
    Type: Application
    Filed: October 22, 2010
    Publication date: May 26, 2011
    Applicant: Abbott GmbH & Co. KG
    Inventors: Jochen G. Salfeld, Michael Roguska, Michael Paskind, Subhashis Banerjee, Daniel Edward Tracey, Michael White, Zehra Edward Kaymakcalan, Boris Labkovsky, Paul Sakorafas, Geertuida M. Veldman, Amy Venturini, Angela Widom, Stuart Friedrich, Nicholas W. Warne, Angela Kantor, John Gawain Elvin, Alexander Robert Duncan, Elaine Joy Derbyshire, Sara Carmen, Stephen Smith, Thor Las Holtet, Sarah Leila Du Fou
  • Patent number: 7883704
    Abstract: Human antibodies, preferably recombinant human antibodies, that specifically bind to human interleukin-12 (hIL-12 ) are disclosed. Preferred antibodies have high affinity for hIL-12 and neutralize hIL-12 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and for inhibiting hIL-12 activity, e.g., in a human subject suffering from a disorder in which hIL-12 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.
    Type: Grant
    Filed: December 22, 2006
    Date of Patent: February 8, 2011
    Assignee: Abbott GmbH & Co. KG
    Inventors: Jochen G. Salfeld, Michael Roguska, Michael Paskind, Subhashis Banerjee, Daniel Edward Tracey, Michael White, Zehra Kaymakcalan, Boris Labkovsky, Paul Sakorafas, Geertruida M. Veldman, Amy Venturini, Angela Widom, Stuart Friedrich, Nicholas W. Warne, Angela Kantor, John Gawain Elvin, Alexander Robert Duncan, Elaine Joy Derbyshire, Sara Carmen, Stephen Smith, Thor Las Holtet, Sarah Leila Du Fou
  • Patent number: 7504485
    Abstract: Human antibodies, preferably recombinant human antibodies, that specifically bind to human interleukin-12 (hIL-12) are disclosed. Preferred antibodies have high affinity for hIL-12 and neutralize hIL-12 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and for inhibiting hIL-12 activity, e.g., in a human subject suffering from a disorder in which hIL-12 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.
    Type: Grant
    Filed: July 1, 2004
    Date of Patent: March 17, 2009
    Assignee: Abbott GmbH & Co., KG
    Inventors: Jochen G. Salfeld, Michael Roguska, Michael Paskind, Subhashis Banerjee, Daniel Edward Tracey, Michael White, Zehra Kaymakcalan, Boris Labkovsky, Paul Sakorafas, Geertruida M. Veldman, Amy Venturini, Angela Widom, Stuart Friedrich, Nicholas W. Warne, Angela Myles, John Gawain Elvin, Alexander Robert Duncan, Elaine J. Derbyshire, Sara Carmen, Stephen Smith, Thor Las Holtet, Sarah Leila Du Fou
  • Publication number: 20080193466
    Abstract: Methods for treating anemia in which TNF? activity is detrimental are described.
    Type: Application
    Filed: April 14, 2008
    Publication date: August 14, 2008
    Applicant: ABBOTT BIOTECHNOLOGY LTD.
    Inventors: Subhashis Banerjee, Lori K. Taylor, Clive E. Spiegler, Daniel Edward Tracey, Elliot K. Chartash, Rebacca S. Hoffman, William T. Barchuk, Philip Yan, Anwar Murtaza, Jochen G. Salfeld, Steven Fischkoff
  • Publication number: 20040219142
    Abstract: Methods of treating TNF&agr;-related skin and nail disorders are described.
    Type: Application
    Filed: July 18, 2003
    Publication date: November 4, 2004
    Applicants: Abbott Laboratories S.A., Abbott Biotechnology Ltd.
    Inventors: Subhashis Banerjee, Lori K. Taylor, Clive E. Spiegler, Daniel Edward Tracey, Elliot K. Chartash, Rebecca S. Hoffman, William T. Barchuk, Philip Yan, Anwar Murtaza, Jochen G. Salfeld, Steven Fischkoff
  • Publication number: 20040151722
    Abstract: Methods for treating metabolic disorders, including diabetes and obesity, using TNF&agr; inhibitors are described.
    Type: Application
    Filed: July 18, 2003
    Publication date: August 5, 2004
    Applicant: Abbott Biotechnology Ltd.
    Inventors: Subhashis Banerjee, Lori K. Taylor, Clive E. Spiegler, Daniel Edward Tracey, Elliot K. Chartash, Rebecca S. Hoffman, William T. Barchuk, Philip Yan, Anwar Murtaza, Jochen G. Salfeld, Steven Fischkoff
  • Publication number: 20040136991
    Abstract: Methods for treating anemia in which TNF&agr; activity is detrimental are described.
    Type: Application
    Filed: July 18, 2003
    Publication date: July 15, 2004
    Applicant: Abbott Biotechnology Ltd.
    Inventors: Subhashis Banerjee, Lori K. Taylor, Clive E. Spiegler, Daniel Edward Tracey, Elliot K. Chartash, Rebecca S. Hoffman, William T. Barchuk, Philip Yan, Anwar Murtaza, Jochen G. Salfeld, Steven Fischkoff
  • Publication number: 20040136989
    Abstract: Methods for treating vasculitides in which TNF&agr; activity is detrimental are described.
    Type: Application
    Filed: July 18, 2003
    Publication date: July 15, 2004
    Applicant: Abbott Laboratories S.A.
    Inventors: Subhashis Banerjee, Lori K. Taylor, Clive E. Spiegler, Daniel Edward Tracey, Elliot Keith Chartash, Rebecca S. Hoffman, William T. Barchuk, Philip Yan, Anwar Murtaza, Jochen G. Salfeld, Steven Fischkoff
  • Publication number: 20040136990
    Abstract: Methods for treating pain syndromes in which TNF&agr; activity is detrimental are described.
    Type: Application
    Filed: July 18, 2003
    Publication date: July 15, 2004
    Applicant: Abbott Biotechnology Ltd.
    Inventors: Subhashis Banerjee, Lori K. Taylor, Clive E. Spiegler, Daniel Edward Tracey, Elliot K. Chartash, Rebecca S. Hoffman, William T. Barchuk, Philip Yan, Anwar Murtaza, Jochen G. Salfeld, Steven Fischkoff
  • Publication number: 20040131614
    Abstract: Methods of treating pulmonary disorders comprising administering TNF&agr; inhibitors, including TNF&agr; antibodies are described.
    Type: Application
    Filed: July 18, 2003
    Publication date: July 8, 2004
    Applicant: Abbott Biotechnology Ltd.
    Inventors: Subhashis Banerjee, Lori K. Taylor, Clive E. Spiegler, Daniel Edward Tracey, Elliot Keith Chartash, Rebecca S. Hoffman, William T. Barchuk, Philip Yan, Anwar Murtaza, Jochen G. Salfeld, Steven Fischkoff
  • Publication number: 20040126372
    Abstract: Methods of treating TNF&agr;-related disorders comprising administering TNF&agr; inhibitors, including TNF&agr; antibodies are described.
    Type: Application
    Filed: July 18, 2003
    Publication date: July 1, 2004
    Applicant: Abbott Biotechnology Ltd.
    Inventors: Subhashis Banerjee, Lori K. Taylor, Clive E. Spiegler, Daniel Edward Tracey, Elliot K. Chartash, Rebecca S. Hoffman, William T. Barchuk, Philip Yan, Anwar Murtaza, Jochen G. Salfeld, Steven Fischkoff
  • Publication number: 20040126373
    Abstract: Methods for treating coronary disease in which TNF&agr; activity is detrimental are described.
    Type: Application
    Filed: July 18, 2003
    Publication date: July 1, 2004
    Applicant: Abbott Biotechnology Ltd.
    Inventors: Subhashis Banerjee, Lori K. Taylor, Clive E. Spiegler, Daniel Edward Tracey, Elliot K. Chartash, Rebecca S. Hoffman, William T. Barchuk, Philip Yan, Anwar Murtaza, Jochen G. Salfeld, Steven Fischkoff